Health
Medical
Technology

Fulgent Genetics

$5.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-3.38%) Today
+$0.10 (1.84%) After Hours

Why Robinhood?

You can buy or sell FLGT and other stocks, options, ETFs, and crypto commission-free!

About

Fulgent Genetics, Inc. Common Stock, also called Fulgent Genetics, is a technology company, which focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. Read More Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Employees
98
Headquarters
Temple City, California
Founded
2016
Market Cap
101.48M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
13.62K
High Today
$5.75
Low Today
$5.40
Open Price
$5.62
Volume
3.68K
52 Week High
$6.12
52 Week Low
$3.02

Collections

Health
Medical
Technology
Software Service
2016 IPO
US
North America

News

Simply Wall StMar 13

Does Fulgent Genetics, Inc. (NASDAQ:FLGT) Have A Volatile Share Price?

If you’re interested in Fulgent Genetics, Inc. (NASDAQ:FLGT), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the port...

27
MarketBeatMar 5

Stock Price, News, & Analysis for Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, C...

3
Seeking AlphaMar 2

Fulgent Genetics' (FLGT) CEO Ming Hsieh on Q4 2018 Results - Earnings Call Transcript

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Nicole Borsje – Head of Investor Relations Ming Hsieh – Chief Executive Officer Paul Kim – Chief Financial Officer Conference Call Participants Bill Quirk – Piper Jaffray Erin Wright – Credit Suisse Operator Good day, ladies and gentlemen, and welcome to the Fulgent Genetics Fourth Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference call may be...

35

Earnings

-$0.06
-$0.03
-$0.01
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.